Thucydides
Registered User
- Dec 24, 2009
- 8,177
- 860
They are much more then just ebola, they also have good exposure to the Hep B market as well as a cancer drug (I don't know too much about that one though) as well as other drugs. The ebola human trails were put on hold until the breakout, they have had the most success of any other company in terms of primate and humans survival rates (100%) but yes ebola is very much traded by the news and the story is now all but over from the look so it. ZMapp had some success but they are private owned and it takes them a very long time to create the drug.
As I said bio-tech's are very risky, they carry a huge risk-reward ratio, they aren't for your average investor but as you continue to learn it can be a great money maker if you know what you are doing. I'm in no way suggesting you buy it, but it wouldn't hurt to keep an eye on it.
Yes it's possible to enter the field at 31, or 41 for that matter depending on what you want to do as financial advisors will always be in demand and they often don't care what you know but if you can sell.
Thanks. This is encouraging news about entering the financial sector. I'm going to begin signing up for some courses this week.
I only did very little research on the company, but i'll continue to read. Do you have a price in your head that you'd be wanting to get back in at? I would wait until some shorts fell off before buying, in my opinion. I'm going to follow this stock closely, and read more about the biotech sector. I love the reward factor of a good company. I'm still young enough where I don't mind a little risk as long as I am confident in the long term outlook.
What is your view on the mid-term/long-term oil outlook?